{"id":470413,"date":"2021-04-02T16:33:18","date_gmt":"2021-04-02T20:33:18","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=470413"},"modified":"2021-04-02T16:33:18","modified_gmt":"2021-04-02T20:33:18","slug":"dbv-technologies-announces-appointment-of-timothy-e-morris-to-board-of-directors","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/dbv-technologies-announces-appointment-of-timothy-e-morris-to-board-of-directors\/","title":{"rendered":"DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors"},"content":{"rendered":"
\n

Montrouge, France, April 2, 2021
DBV Technologies Announces Appointment of Timothy E. Morris to Board of Directors<\/strong><\/p>\n

DBV Technologies (Euronext: DBV \u2013 ISIN: FR0010417345 \u2013 Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, announced today the provisional appointment of Mr. Timothy E. Morris, as director, by the DBV Board of Directors, effective March 30, 2021. Mr. Morris will serve as a member of the Audit Committee of the Board. With this addition, the Board comprises nine directors.<\/p>\n

\u201cWe are pleased to welcome Tim Morris <\/em>as a new director <\/em>to the DBV Board<\/em>,\u201d said Michel de Rosen, Chairman of DBV Technologies\u2019 Board of Directors. \u201cTim brings to DBV more than 20 years of leadership experience in the biopharma sector and he is highly regarded for his finance and commercial capabilities. We believe he will add tremendous value to our Board and DBV as a whole<\/em>.\u201d<\/p>\n

Mr. Morris has been the Chief Operating Officer and Chief Financial Officer of Humanigen, Inc. since August 2020. Prior to joining Humanigen\u2019s management team, Mr. Morris served as Chair of the Company\u2019s Audit Committee.\u00a0 Mr. Morris has spent more than two decades leading the financial, commercial, and manufacturing functions at several public biopharmaceutical companies, including Iovance, AcelRx, VIVUS, and Questcor (formerly Ribogene). Mr. Morris received his Bachelor of Science in Business with an emphasis in Accounting from California State University, Chico, and is a Certified Public Accountant (Inactive).<\/p>\n

\u201cThe current state of DBV\u2019s European and U.S. regulatory progress and pipeline potential make it an exciting time to join the company<\/em>,\u201d said Timothy Morris. \u201cI am honored to join DBV and look forward to serving as a member of the Board and Audit Committee and contributing to the success of the Company<\/em>.\u201d<\/p>\n

Mr. Morris\u2019 appointment is subject to ratification and will be submitted to a shareholder vote at the Ordinary and Extraordinary General Meeting that DBV Technologies will convene on May 19, 2021.<\/p>\n

\n About DBV Technologies\u00a0<\/strong>
\n
DBV Technologies is developing Viaskin\u2122, an investigational proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT\u2122, DBV Technologies\u2019 method of delivering biologically active compounds to the immune system through intact skin. With this new class of non-invasive product candidates, the Company is dedicated to safely transforming the care of food allergic patients. DBV Technologies\u2019 food allergies programs include ongoing clinical trials of Viaskin Peanut. DBV Technologies has global headquarters in Montrouge, France and offices in Bagneux, France, and North American operations in Summit, NJ and New York, NY. The Company\u2019s ordinary shares are traded on segment B of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and the Company\u2019s ADSs (each representing one-half of one ordinary share) are traded on the Nasdaq Global Select Market (Ticker: DBVT).<\/p>\n

\n Forward-Looking Statements<\/strong>
\n
This press release may contain forward-looking statements, including statements regarding Company\u2019s anticipated Ordinary and Extraordinary General Meeting of Shareholders, DBV\u2019s regulatory progress, and the potential of DBV\u2019s pipeline. These forward-looking statements and estimates are not promises or guarantees and involve substantial risks and uncertainties. Among the factors that could cause actual occurrences to differ materially from those described or projected herein include uncertainties associated generally with research and development, clinical trials and related regulatory reviews and approvals and those associated with scheduling and holding public events, including the impact of the COVID-19 pandemic\u00a0 A further discussion of risks and uncertainties that could cause actual results to differ materially from those set forth in the forward-looking statements in this press release can be found in DBV Technologies\u2019 regulatory filings with the French Autorit\u00e9 des March\u00e9s Financiers, DBV Technologies\u2019 filings and reports with the U.S. Securities and Exchange Commission, including in DBV Technologies\u2019 Annual Report on Form 10-K for the year ended December 31, 2020, and future filings and reports by DBV Technologies. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements and estimates, which speak only as of the date hereof. Other than as required by applicable law, DBV Technologies undertakes no obligation to update or revise the information contained in this Press Release.<\/p>\n

\n Investor Contact <\/strong>
\n
Anne Pollak
DBV Technologies
+1 857-529-2363
anne.pollak@dbv-technologies.com<\/u><\/a><\/p>\n

\n Media Contact<\/strong>
\n
Angela Marcucci
DBV Technologies
+1\u00a0646-842-2393
angela.marcucci@dbv-technologies.com<\/a><\/p>\n

\u00a0<\/p>\n

\n Attachment<\/strong>\n <\/p>\n